Patents by Inventor Michael Downes

Michael Downes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11981931
    Abstract: The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: May 14, 2024
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald Evans, Michael Downes, Yasuyuki Kida, Teruhisa Kawamura, Zong Wei, Ruth T. Yu, Annette R. Atkins
  • Publication number: 20240101962
    Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.
    Type: Application
    Filed: June 23, 2023
    Publication date: March 28, 2024
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald EVANS, Michael DOWNES, Annette ATKINS, Eiji YOSHIHARA, Ruth YU
  • Publication number: 20230373948
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: February 13, 2023
    Publication date: November 23, 2023
    Inventors: Michael Downes, Ronald M. Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • Patent number: 11760977
    Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: September 19, 2023
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Ronald Evans, Michael Downes, Annette Atkins, Eiji Yoshihara, Ruth Yu
  • Patent number: 11685901
    Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: June 27, 2023
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald Evans, Michael Downes, Annette Atkins, Eiji Yoshihara, Ruth Yu
  • Publication number: 20230097335
    Abstract: The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided.
    Type: Application
    Filed: December 2, 2022
    Publication date: March 30, 2023
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sihao Liu, Ruth T. Yu
  • Publication number: 20230078590
    Abstract: The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
    Type: Application
    Filed: July 19, 2022
    Publication date: March 16, 2023
    Applicant: Salk Institute for Biological Studies
    Inventors: Sagar P. BAPAT, Ye ZHENG, Ronald EVANS, Michael DOWNES, Annette R. ATKINS, Ruth T. YU
  • Patent number: 11578052
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: February 14, 2023
    Assignees: Mitobridge, Inc., The Salk Institute for Biological Studies
    Inventors: Michael Downes, Ronald M. Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • Patent number: 11542309
    Abstract: The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: January 3, 2023
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sihao Liu, Ruth T. Yu
  • Publication number: 20220315901
    Abstract: The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency.
    Type: Application
    Filed: December 8, 2020
    Publication date: October 6, 2022
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: RONALD EVANS, MICHAEL DOWNES, YASUYUKI KIDA, TERUHISA KAWAMURA, ZONG WEI, RUTH T. YU, ANNETTE R. ATKINS
  • Patent number: 11440889
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: September 13, 2022
    Assignees: The Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
  • Patent number: 11428697
    Abstract: The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 30, 2022
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Sagar P. Bapat, Ye Zheng, Ronald Evans, Michael Downes, Annette R. Atkins, Ruth T. Yu
  • Patent number: 11420934
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: August 23, 2022
    Assignees: The Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F. W. Keana, Mark G. Bock, Authur F. Kluge, Mike A. Patane
  • Publication number: 20220220446
    Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.
    Type: Application
    Filed: March 28, 2022
    Publication date: July 14, 2022
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald EVANS, Michael DOWNES, Annette ATKINS, Eiji YOSHIHARA, Ruth YU
  • Patent number: 11376264
    Abstract: Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: July 5, 2022
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Zong Wei, Annette Atkins, Ruth T. Yu
  • Publication number: 20210363490
    Abstract: The invention features cells, islet-like cells, pancreatic islets and organoids (e.g., human islet-like organoids or HILOs), as well as cell cultures and methods that are useful for the rapid and reliable generation of cells and organoids, such as pancreatic islets and organoids, that are sustainable in vivo and that evade immune detection, rejection and autoimmunity. The invention also features methods of treating pancreatic diseases, such as type 2 diabetes, and pancreatic cancer, using the cells, islet-like cells, pancreatic islets and organoids (e.g., HILOs) that are designed to modulate the activity of immune cells that would otherwise react against them.
    Type: Application
    Filed: October 11, 2019
    Publication date: November 25, 2021
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Eiji YOSHIHARA, Ruth YU, Michael DOWNES, Ronald EVANS, Annette ATKINS
  • Patent number: 11130779
    Abstract: Provided herein are deuterated compounds and compositions useful in increasing PPAR? activity. The compounds have a formula where L5 comprises at least one deuterium. Exemplary species include The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: September 28, 2021
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes
  • Publication number: 20210253549
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: January 29, 2021
    Publication date: August 19, 2021
    Inventors: Michael Downes, Ronald M. Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • Publication number: 20210147365
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Application
    Filed: September 1, 2020
    Publication date: May 20, 2021
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
  • Patent number: 10920199
    Abstract: The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency. In particular embodiments the invention is predicated upon increased expression of an estrogen related receptor and changes in the oxidative and glycolytic pathways.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: February 16, 2021
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Ronald Evans, Michael Downes, Yasuyuki Kida, Teruhisa Kawamura, Zong Wei, Ruth T. Yu, Annette R. Atkins